Risk factors for colonization and infection with multidrug-resistant Pseudomonas aeruginosa in intensive care unit: protocol for a systematic review and meta-analysis.
Antibiotic resistance
Infection
Intensive care unit
Resistant Pseudomonas aeruginosa
Risk factors
multidrug resistance
Journal
Systematic reviews
ISSN: 2046-4053
Titre abrégé: Syst Rev
Pays: England
ID NLM: 101580575
Informations de publication
Date de publication:
13 12 2022
13 12 2022
Historique:
received:
08
03
2021
accepted:
25
11
2022
entrez:
13
12
2022
pubmed:
14
12
2022
medline:
16
12
2022
Statut:
epublish
Résumé
Infection with resistant Pseudomonas aeruginosa (RPA) in the intensive care unit (ICU) is known to be either endogenous or exogenous or both, but the roles of each of these contamination routes are yet to be clarified. Data regarding prevalence, risk factors, and environmental factors associated with RPA in ICU are very scanty and even when they exist, they seem to be contradictory. So, there is a strong interest in understanding both individual and environmental factors associated with RPA infection. This systematic review aims to investigate individual and environmental factors associated with the colonization and infection with RPA in ICU. MEDLINE (Pubmed), EMBASE (OVID), the Cochrane Library (Wiley), Web of Science, CINAHL (EBSCOHost), and LILACS (BIREME) will be searched from inception onwards. Grey literature will be identified through Google Scholar and Open Grey. Two reviewers will independently screen all citations, abstracts, and full-text articles. Potential conflicts will be resolved through discussion. Methodological quality including bias will be appraised using appropriate approaches. A narrative synthesis will describe the quality and content of the epidemiological evidence. Prevalence, odds ratio, relative risk, and hazard radio with their respective 95% confidence intervals will be calculated. A meta-analysis of data extracted from eligible studies with similar populations and RPA testing will be performed. The analysis will evaluate factors influencing the estimates. A random effect model will be used to summarize effect sizes. Two contrasting hypotheses on risk factors of acquisition, colonization, and infection of RPA are being debated, especially in a context where available data are scanty or exhibit high discrepancy. Indeed, most of the reviews have been focalized on hospitalized patients, and not in ICU, and few of them address the issue of environmental factors. To fill that gap, this review will combine both analyses of individual and environmental risk factors using prevalence studies in ICU and evaluation of different methodologies. These two hypotheses will be tested and challenged and could serve as a basis for a more in-depth study to fill the methodological gaps that will be identified as part of this current review. This protocol has been submitted to the Prospective Register of Systematic Reviews (PROSPERO) and the registration number attributed was CRD42021233832 of 07 March 2021.
Sections du résumé
BACKGROUND
Infection with resistant Pseudomonas aeruginosa (RPA) in the intensive care unit (ICU) is known to be either endogenous or exogenous or both, but the roles of each of these contamination routes are yet to be clarified. Data regarding prevalence, risk factors, and environmental factors associated with RPA in ICU are very scanty and even when they exist, they seem to be contradictory. So, there is a strong interest in understanding both individual and environmental factors associated with RPA infection. This systematic review aims to investigate individual and environmental factors associated with the colonization and infection with RPA in ICU.
METHODOLOGY
MEDLINE (Pubmed), EMBASE (OVID), the Cochrane Library (Wiley), Web of Science, CINAHL (EBSCOHost), and LILACS (BIREME) will be searched from inception onwards. Grey literature will be identified through Google Scholar and Open Grey. Two reviewers will independently screen all citations, abstracts, and full-text articles. Potential conflicts will be resolved through discussion. Methodological quality including bias will be appraised using appropriate approaches. A narrative synthesis will describe the quality and content of the epidemiological evidence. Prevalence, odds ratio, relative risk, and hazard radio with their respective 95% confidence intervals will be calculated. A meta-analysis of data extracted from eligible studies with similar populations and RPA testing will be performed. The analysis will evaluate factors influencing the estimates. A random effect model will be used to summarize effect sizes.
DISCUSSION
Two contrasting hypotheses on risk factors of acquisition, colonization, and infection of RPA are being debated, especially in a context where available data are scanty or exhibit high discrepancy. Indeed, most of the reviews have been focalized on hospitalized patients, and not in ICU, and few of them address the issue of environmental factors. To fill that gap, this review will combine both analyses of individual and environmental risk factors using prevalence studies in ICU and evaluation of different methodologies. These two hypotheses will be tested and challenged and could serve as a basis for a more in-depth study to fill the methodological gaps that will be identified as part of this current review.
SYSTEMATIC REVIEW REGISTRATION
This protocol has been submitted to the Prospective Register of Systematic Reviews (PROSPERO) and the registration number attributed was CRD42021233832 of 07 March 2021.
Identifiants
pubmed: 36514175
doi: 10.1186/s13643-022-02143-8
pii: 10.1186/s13643-022-02143-8
pmc: PMC9749282
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
270Informations de copyright
© 2022. The Author(s).
Références
PLoS One. 2018 Mar 9;13(3):e0193300
pubmed: 29522559
Antimicrob Agents Chemother. 2006 Jan;50(1):43-8
pubmed: 16377665
PLoS Med. 2009 Jul 21;6(7):e1000097
pubmed: 19621072
Clin Microbiol Infect. 2011 Jan;17(1):57-62
pubmed: 20121820
BMC Infect Dis. 2020 Sep 22;20(1):693
pubmed: 32962640
Antimicrob Agents Chemother. 2005 Apr;49(4):1306-11
pubmed: 15793102
J Hosp Infect. 2020 Nov;106(3):454-464
pubmed: 32898614
Expert Rev Pharmacoecon Outcomes Res. 2010 Aug;10(4):441-51
pubmed: 20715920
PLoS One. 2011;6(10):e25617
pubmed: 21984923
J Gen Microbiol. 1966 May;43(2):159-271
pubmed: 5963505
Intensive Care Med. 2001 Aug;27(8):1263-8
pubmed: 11511937
Lancet. 2022 Feb 12;399(10325):629-655
pubmed: 35065702
Eur J Clin Microbiol Infect Dis. 2017 Jul;36(7):1097-1104
pubmed: 28093651
BMJ. 2015 Jan 02;350:g7647
pubmed: 25555855
Antimicrob Resist Infect Control. 2018 Jul 4;7:79
pubmed: 29997889
Open Microbiol J. 2007;1:8-11
pubmed: 19088898
Antimicrob Resist Infect Control. 2017 Jan 11;6:7
pubmed: 28096975
Indian J Med Res. 2015 Apr;141(4):491
pubmed: 26112856